| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroendocrine Tumors | 25 | 2023 | 51 | 10.290 |
Why?
|
| Pancreatic Neoplasms | 25 | 2022 | 98 | 9.220 |
Why?
|
| Adrenal Cortex Neoplasms | 4 | 2020 | 13 | 2.660 |
Why?
|
| Adrenocortical Carcinoma | 4 | 2020 | 14 | 2.650 |
Why?
|
| Thyroid Neoplasms | 12 | 2023 | 46 | 2.330 |
Why?
|
| Intestinal Neoplasms | 5 | 2020 | 11 | 2.220 |
Why?
|
| Stomach Neoplasms | 5 | 2020 | 35 | 2.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 7 | 2022 | 34 | 1.830 |
Why?
|
| Organometallic Compounds | 7 | 2020 | 19 | 1.820 |
Why?
|
| Pancreatectomy | 5 | 2020 | 14 | 1.640 |
Why?
|
| Pancreas | 4 | 2019 | 33 | 1.290 |
Why?
|
| Thyroid Nodule | 5 | 2023 | 9 | 1.270 |
Why?
|
| Thyroidectomy | 6 | 2022 | 19 | 1.110 |
Why?
|
| Humans | 59 | 2023 | 28449 | 1.080 |
Why?
|
| Middle Aged | 31 | 2023 | 9316 | 1.050 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2020 | 15 | 1.040 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 372 | 1.030 |
Why?
|
| Liver Neoplasms | 4 | 2023 | 105 | 1.020 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 202 | 1.010 |
Why?
|
| Radiopharmaceuticals | 4 | 2020 | 54 | 0.960 |
Why?
|
| Female | 38 | 2023 | 15777 | 0.960 |
Why?
|
| Male | 35 | 2023 | 15352 | 0.940 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2022 | 13 | 0.940 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2016 | 6 | 0.940 |
Why?
|
| Retrospective Studies | 19 | 2023 | 3615 | 0.940 |
Why?
|
| von Hippel-Lindau Disease | 3 | 2021 | 6 | 0.870 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 35 | 0.820 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 2 | 2020 | 4 | 0.810 |
Why?
|
| MicroRNAs | 4 | 2023 | 54 | 0.810 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 17 | 0.800 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 42 | 0.780 |
Why?
|
| Aged | 24 | 2021 | 9320 | 0.770 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 4 | 0.710 |
Why?
|
| Octreotide | 1 | 2020 | 1 | 0.700 |
Why?
|
| Coordination Complexes | 1 | 2020 | 2 | 0.700 |
Why?
|
| Adrenalectomy | 1 | 2019 | 4 | 0.680 |
Why?
|
| Margins of Excision | 1 | 2020 | 31 | 0.680 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 81 | 0.670 |
Why?
|
| Adult | 25 | 2021 | 8155 | 0.660 |
Why?
|
| Insulinoma | 2 | 2016 | 2 | 0.650 |
Why?
|
| Mutation | 6 | 2023 | 349 | 0.640 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 15 | 0.630 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 3 | 0.630 |
Why?
|
| Parathyroid Hormone | 2 | 2016 | 25 | 0.630 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 24 | 0.620 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 36 | 0.610 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 122 | 0.600 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 46 | 0.600 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 64 | 0.590 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 190 | 0.580 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 108 | 0.570 |
Why?
|
| Postoperative Complications | 4 | 2023 | 935 | 0.560 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2013 | 61 | 0.560 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2016 | 1 | 0.540 |
Why?
|
| Thyroid Gland | 3 | 2016 | 42 | 0.540 |
Why?
|
| United States | 7 | 2023 | 2185 | 0.530 |
Why?
|
| Catheterization | 2 | 2014 | 45 | 0.530 |
Why?
|
| Surgeons | 3 | 2023 | 89 | 0.530 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2015 | 1 | 0.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 113 | 0.520 |
Why?
|
| Hepatectomy | 5 | 2023 | 64 | 0.480 |
Why?
|
| Survival Rate | 4 | 2020 | 356 | 0.470 |
Why?
|
| Viscera | 1 | 2014 | 2 | 0.460 |
Why?
|
| Reperfusion | 1 | 2014 | 7 | 0.460 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2014 | 20 | 0.450 |
Why?
|
| Tissue and Organ Procurement | 1 | 2014 | 34 | 0.450 |
Why?
|
| Organ Transplantation | 1 | 2014 | 33 | 0.440 |
Why?
|
| Carcinoma | 4 | 2023 | 70 | 0.440 |
Why?
|
| Pathology, Molecular | 1 | 2013 | 3 | 0.440 |
Why?
|
| Adolescent | 10 | 2021 | 2324 | 0.420 |
Why?
|
| Prognosis | 8 | 2021 | 826 | 0.420 |
Why?
|
| Survival Analysis | 3 | 2021 | 268 | 0.420 |
Why?
|
| Calcimimetic Agents | 1 | 2012 | 1 | 0.400 |
Why?
|
| Databases, Factual | 5 | 2021 | 358 | 0.390 |
Why?
|
| Carcinoma, Papillary | 6 | 2016 | 23 | 0.390 |
Why?
|
| Reoperation | 1 | 2016 | 917 | 0.390 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 4 | 2021 | 8 | 0.390 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 1870 | 0.360 |
Why?
|
| Aspergillosis | 2 | 2008 | 13 | 0.360 |
Why?
|
| Hematologic Neoplasms | 2 | 2008 | 19 | 0.360 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2010 | 3 | 0.350 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2010 | 11 | 0.350 |
Why?
|
| Colectomy | 1 | 2010 | 23 | 0.350 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 1197 | 0.340 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 177 | 0.330 |
Why?
|
| Young Adult | 10 | 2021 | 2103 | 0.320 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 334 | 0.320 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 114 | 0.300 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 276 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 244 | 0.300 |
Why?
|
| Treatment Outcome | 9 | 2020 | 3619 | 0.300 |
Why?
|
| Prospective Studies | 7 | 2022 | 1802 | 0.300 |
Why?
|
| Latex Fixation Tests | 1 | 2007 | 1 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 321 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 100 | 0.280 |
Why?
|
| Risk Factors | 5 | 2020 | 2414 | 0.260 |
Why?
|
| Postoperative Period | 2 | 2019 | 331 | 0.260 |
Why?
|
| Genotype | 2 | 2017 | 349 | 0.250 |
Why?
|
| SEER Program | 2 | 2015 | 41 | 0.250 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 58 | 0.250 |
Why?
|
| Child | 3 | 2021 | 1424 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 179 | 0.240 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 494 | 0.240 |
Why?
|
| Parathyroidectomy | 2 | 2016 | 11 | 0.240 |
Why?
|
| Hemangioblastoma | 2 | 2021 | 2 | 0.230 |
Why?
|
| Positron-Emission Tomography | 3 | 2020 | 90 | 0.230 |
Why?
|
| Pheochromocytoma | 2 | 2021 | 7 | 0.230 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2021 | 11 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2020 | 12 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 772 | 0.230 |
Why?
|
| Propensity Score | 2 | 2021 | 36 | 0.230 |
Why?
|
| Animals | 3 | 2021 | 3808 | 0.220 |
Why?
|
| Liver | 2 | 2017 | 160 | 0.220 |
Why?
|
| Bone Density | 2 | 2016 | 149 | 0.210 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2023 | 8 | 0.210 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2022 | 1 | 0.200 |
Why?
|
| Tumor Burden | 2 | 2019 | 28 | 0.200 |
Why?
|
| Hashimoto Disease | 2 | 2020 | 5 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 5 | 0.200 |
Why?
|
| DNA Repair | 1 | 2022 | 7 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 5 | 0.200 |
Why?
|
| Transcriptome | 2 | 2020 | 88 | 0.200 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 28 | 0.190 |
Why?
|
| Operative Time | 2 | 2019 | 93 | 0.190 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 91 | 0.190 |
Why?
|
| Chondroitin Sulfates | 1 | 2021 | 6 | 0.190 |
Why?
|
| Hydrogels | 1 | 2021 | 7 | 0.190 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 102 | 0.190 |
Why?
|
| Jejunal Neoplasms | 1 | 2021 | 2 | 0.190 |
Why?
|
| Ileal Neoplasms | 1 | 2021 | 3 | 0.190 |
Why?
|
| Chromogranin A | 1 | 2021 | 10 | 0.190 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 354 | 0.190 |
Why?
|
| Calcium | 2 | 2016 | 379 | 0.190 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 31 | 0.180 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 2 | 0.180 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 140 | 0.180 |
Why?
|
| ras Proteins | 1 | 2020 | 10 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 80 | 0.180 |
Why?
|
| Adrenal Cortex | 1 | 2020 | 3 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 4 | 0.180 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 251 | 0.180 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 2 | 0.180 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 53 | 0.170 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 364 | 0.170 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 519 | 0.170 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 36 | 0.170 |
Why?
|
| Mitotane | 1 | 2019 | 3 | 0.170 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 166 | 0.170 |
Why?
|
| Registries | 1 | 2021 | 190 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 133 | 0.170 |
Why?
|
| Whole Genome Sequencing | 1 | 2019 | 5 | 0.160 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 16 | 0.160 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 11 | 0.160 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 5 | 0.160 |
Why?
|
| RNA-Binding Proteins | 1 | 2019 | 25 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2019 | 45 | 0.160 |
Why?
|
| Adrenal Glands | 1 | 2018 | 8 | 0.160 |
Why?
|
| Serum Albumin | 1 | 2019 | 24 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 66 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 4881 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 306 | 0.160 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 11 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 27 | 0.160 |
Why?
|
| Repressor Proteins | 1 | 2019 | 37 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 67 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2019 | 90 | 0.150 |
Why?
|
| Patient Selection | 1 | 2019 | 209 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 1 | 0.150 |
Why?
|
| Gene Ontology | 1 | 2017 | 1 | 0.150 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 5 | 0.150 |
Why?
|
| Cluster Analysis | 1 | 2017 | 43 | 0.150 |
Why?
|
| Hypertrophy | 1 | 2017 | 24 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 25 | 0.140 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 24 | 0.140 |
Why?
|
| Time Factors | 2 | 2018 | 1499 | 0.140 |
Why?
|
| Liver Regeneration | 1 | 2017 | 25 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2019 | 164 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 113 | 0.140 |
Why?
|
| Portal Vein | 1 | 2017 | 47 | 0.140 |
Why?
|
| Mice | 1 | 2021 | 1475 | 0.140 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2016 | 11 | 0.130 |
Why?
|
| Intraoperative Period | 1 | 2016 | 27 | 0.130 |
Why?
|
| Parathyroid Glands | 1 | 2016 | 8 | 0.130 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 43 | 0.130 |
Why?
|
| Lymph Node Excision | 2 | 2021 | 27 | 0.130 |
Why?
|
| Goiter | 1 | 2016 | 3 | 0.130 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 371 | 0.130 |
Why?
|
| Pancreatic Cyst | 1 | 2016 | 5 | 0.130 |
Why?
|
| Incidence | 1 | 2019 | 772 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 25 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2022 | 1936 | 0.130 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 168 | 0.130 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 9 | 0.130 |
Why?
|
| Laparoscopy | 2 | 2019 | 198 | 0.130 |
Why?
|
| Support Vector Machine | 2 | 2012 | 7 | 0.120 |
Why?
|
| Recurrence | 1 | 2016 | 320 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2016 | 68 | 0.120 |
Why?
|
| Ribonuclease III | 1 | 2014 | 2 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 5 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 138 | 0.120 |
Why?
|
| Phenotype | 1 | 2016 | 309 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 105 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2016 | 236 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 555 | 0.110 |
Why?
|
| Splenomegaly | 1 | 2013 | 6 | 0.110 |
Why?
|
| Proteins | 1 | 2013 | 66 | 0.110 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2013 | 3 | 0.110 |
Why?
|
| Splenectomy | 1 | 2013 | 7 | 0.110 |
Why?
|
| Intestinal Obstruction | 1 | 2012 | 12 | 0.100 |
Why?
|
| Hernia, Inguinal | 1 | 2012 | 23 | 0.100 |
Why?
|
| Abdominal Injuries | 1 | 2012 | 5 | 0.100 |
Why?
|
| Hemostasis, Surgical | 1 | 2012 | 15 | 0.100 |
Why?
|
| Intestine, Small | 1 | 2012 | 34 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 32 | 0.100 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 14 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2011 | 58 | 0.100 |
Why?
|
| Choristoma | 1 | 2011 | 5 | 0.090 |
Why?
|
| Duodenal Neoplasms | 1 | 2011 | 6 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 235 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 60 | 0.090 |
Why?
|
| Adenoma | 1 | 2012 | 61 | 0.090 |
Why?
|
| Logistic Models | 1 | 2012 | 399 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2011 | 177 | 0.090 |
Why?
|
| Disease Progression | 3 | 2018 | 721 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 146 | 0.080 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 87 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 206 | 0.080 |
Why?
|
| Aspergillus flavus | 1 | 2008 | 4 | 0.080 |
Why?
|
| Neutropenia | 1 | 2008 | 19 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2008 | 13 | 0.080 |
Why?
|
| Equipment and Supplies | 1 | 2008 | 10 | 0.080 |
Why?
|
| Biofilms | 1 | 2008 | 16 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2008 | 44 | 0.080 |
Why?
|
| Fractures, Ununited | 1 | 2008 | 16 | 0.070 |
Why?
|
| Computer Simulation | 2 | 2020 | 204 | 0.070 |
Why?
|
| Scaphoid Bone | 1 | 2008 | 25 | 0.070 |
Why?
|
| Galactose | 1 | 2007 | 5 | 0.070 |
Why?
|
| Bacteremia | 1 | 2008 | 101 | 0.070 |
Why?
|
| Mannans | 1 | 2007 | 15 | 0.070 |
Why?
|
| Bone Screws | 1 | 2008 | 151 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2019 | 102 | 0.070 |
Why?
|
| Quality of Life | 2 | 2022 | 663 | 0.070 |
Why?
|
| Sinusitis | 1 | 2008 | 162 | 0.060 |
Why?
|
| Bone Transplantation | 1 | 2008 | 221 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 376 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 38 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2022 | 13 | 0.050 |
Why?
|
| Monitoring, Intraoperative | 1 | 2022 | 37 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2022 | 5 | 0.050 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 6 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2021 | 81 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 8 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 32 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 22 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2020 | 6 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2020 | 12 | 0.040 |
Why?
|
| North America | 1 | 2020 | 43 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 121 | 0.040 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 2 | 0.040 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 4 | 0.040 |
Why?
|
| Unsupervised Machine Learning | 1 | 2019 | 1 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 54 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 59 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 152 | 0.040 |
Why?
|
| Maryland | 1 | 2017 | 7 | 0.040 |
Why?
|
| Portal Pressure | 1 | 2017 | 5 | 0.040 |
Why?
|
| Liver Circulation | 1 | 2017 | 6 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 49 | 0.040 |
Why?
|
| Ligation | 1 | 2017 | 38 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 1 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2017 | 1 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 146 | 0.040 |
Why?
|
| Swine | 1 | 2017 | 81 | 0.040 |
Why?
|
| Organ Size | 1 | 2017 | 108 | 0.040 |
Why?
|
| Random Allocation | 1 | 2017 | 129 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 329 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 33 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 32 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 727 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 52 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 31 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 234 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 189 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 148 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 107 | 0.030 |
Why?
|
| Bilirubin | 1 | 2012 | 11 | 0.030 |
Why?
|
| Liver Failure | 1 | 2012 | 11 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 16 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2012 | 1 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2012 | 9 | 0.020 |
Why?
|
| Italy | 1 | 2012 | 14 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2012 | 9 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2012 | 9 | 0.020 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2012 | 2 | 0.020 |
Why?
|
| Decision Trees | 1 | 2012 | 15 | 0.020 |
Why?
|
| PAX8 Transcription Factor | 1 | 2011 | 1 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2011 | 3 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2012 | 43 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 13 | 0.020 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2011 | 8 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 58 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 6 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 63 | 0.020 |
Why?
|
| Angiography | 1 | 2012 | 33 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2011 | 35 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2012 | 66 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 11 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2012 | 49 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 147 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 145 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 181 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2011 | 31 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2012 | 294 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 378 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 674 | 0.020 |
Why?
|
| Citric Acid | 1 | 2008 | 1 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 2008 | 4 | 0.020 |
Why?
|
| Edetic Acid | 1 | 2008 | 3 | 0.020 |
Why?
|
| Hand Strength | 1 | 2008 | 61 | 0.020 |
Why?
|
| Wrist Joint | 1 | 2008 | 62 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2008 | 725 | 0.010 |
Why?
|